Document is current
Any future updates will be listed below
-
Authors
Lund, Marie https://orcid.org/0000-0001-7417-8889
Corn, Giulia
Jensen, Maj-Britt
Petersen, Tonny
Dalhoff, Kim
Ejlertsen, Bent
Køber, Lars
Wohlfahrt, Jan
Melbye, Mads
-
Funding
Funding for this research was provided by:
Bispebjerg and Frederiksberg Hospital
Kræftens Bekæmpelse (R303-A17352)
Fonden til Lægevidenskabens Fremme (L-2021-00174)
Aase og Ejnar Danielsens Fond (20-10-0416)
Helsefonden (21-B-0290)
Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat
Statens Serum Institut
- License Information
-
More Information
Article History
Received: 4 November 2024
Accepted: 1 April 2025
First Online: 21 May 2025
Declarations
:
: ML declares funding related to the present manuscript from intramural funds at Bispebjerg and Frederiksberg Hospital, Kræftens Bekæmpelse, Fonden til Lægevidenskabens Fremme, Aase og Ejnar Danielsens Fond, Helsefonden and Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat. M-BJ declares participation in advisory board (Novartis) outside the present manuscript. LK declares speakers fee from Astra Zeneca, Boehringer, Novartis and Novo, outside the present manuscript. BE declares receipt of institutional grants from Danish Cancer Society, Astra Zeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen outside the present manuscript, travel grants from Daiichi Sankyo, MSD and Pfizer outside the present manuscript, participation in advisory board (Eli Lilly) outside the present manuscript, and being director of the Danish Breast Cancer Group. Remaining authors declare no potential conflicts of interest.
: The study was approved by Statens Serum Institut’s Data Protection and Information Security Department; under Danish law, neither informed consent nor ethics committee approval is required for strictly register-based studies.
